Mineralys Therapeutics(US:MLYS) Globenewswire·2025-10-21 12:00Core Insights - Mineralys Therapeutics, Inc. is focused on developing treatments for hypertension and related comorbidities, with a key product candidate, lorundrostat, being evaluated in clinical trials [1][4] Group 1: Clinical Trials and Presentations - Data from the Phase 2 Explore-CKD trial of lorundrostat will be presented at the ASN Kidney Week 2025, highlighting its safety and efficacy in participants with hypertension and comorbid CKD [1][6] - The Phase 3 Launch-HTN trial data of lorundrostat will also be featured in a prominent session at ASN Kidney Week, showcasing its relevance in treating uncontrolled hypertension [2][6] Group 2: Product Information - Lorundrostat is a proprietary, orally administered aldosterone synthase inhibitor designed to treat uncontrolled hypertension, chronic kidney disease, and obstructive sleep apnea [3][4] - It exhibits a 374-fold selectivity for aldosterone-synthase inhibition compared to cortisol-synthase inhibition and has shown a 40-70% reduction in plasma aldosterone concentration in hypertensive participants [3]